Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-28

Study Completion Date

2023-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease

NCT02751060

Coronary Disease

ENROLLING_BY_INVITATION

The Use of Blood Biochemical Markers for Diagnostics of Heart Muscle Diseases

NCT05726695

Heart Failure Heart Dilation Left Ventricular Hypertrophy

UNKNOWN

Genetics of Ischemic Cardiomyopathy

NCT05508269

Ischemic Cardiomyopathy

COMPLETED

Circulating microRNAs and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease

NCT03635255

miRNA

RECRUITING

Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome

NCT02755207

Acute Coronary Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, \> 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Group

The study group included 10 patients,

1. men and women
2. between age of 35-60 year
3. chest pain lasting for at least 30 minutes,
4. electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)

No intervention

Intervention Type OTHER

Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Control Group

The study group included 10 patients,

1. men and women
2. between age of 35-60 year
3. having no complaint of health issue,

No intervention

Intervention Type OTHER

Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Expression of miR-133a & 208b

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital
2. Acute episode of Myocardial Infarction
3. With No history of previous Myocardial Infarction Treatment

Exclusion Criteria

1. Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams 2. University hospital
2. Previously Known patients of Myocardial infacrtion
3. Previous medication

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes